GO:1901327 response to tacrolimus: Immunosuppressive Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901327 (response to tacrolimus) describes any cellular or organismal process that changes state or activity in response to tacrolimus (FK506), a calcineurin-inhibiting immunosuppressant [1,2].
• Tacrolimus response is clinically central in transplantation, autoimmune diseases, and inflammatory skin disorders such as vitiligo and atopic dermatitis [3,5,8].
• Response variability is well documented: once- vs twice-daily topical tacrolimus produces different outcomes in vitiligo, and low serum IgE plus inadequately controlled disease predicts proactive topical tacrolimus failure in atopic dermatitis.
• In lupus nephritis, tacrolimus-based induction (alone or with mycophenolate mofetil) shows comparable treatment response to cyclophosphamide but with different serious infection profiles.
• Tacrolimus drug levels correlate with treatment response in childhood steroid-resistant nephrotic syndrome, supporting therapeutic drug monitoring.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes and pathways underlying tacrolimus response [1,2,5].
Description
GO:1901327, response to tacrolimus, is a biological process defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tacrolimus stimulus [1,2]. Tacrolimus (also known as FK506) is a macrolide immunosuppressant widely used in transplantation and immune-mediated diseases, and its effects span transcriptional, secretory, and metabolic responses [2,7]. Understanding this GO term is essential because tacrolimus response is not uniform: clinical studies show that once- versus twice-daily topical application yields different response rates in vitiligo, and that baseline immune and disease-activity features predict failure of proactive topical tacrolimus in atopic dermatitis. In childhood steroid-resistant nephrotic syndrome, tacrolimus drug levels correlate with treatment response, highlighting dose- and exposure-dependent biology. In lupus nephritis, tacrolimus-based induction regimens produce treatment responses comparable to cyclophosphamide but with distinct safety profiles. These observations underscore the need for mechanistic, gene-level studies of response to tacrolimus. This article integrates the QuickGO definition with verified PubMed evidence to outline the mechanisms, key genes, disease links, and CRISPR-based research methods relevant to GO:1901327.
response to tacrolimus At A Glance
| GO ID | GO:1901327 |
|---|---|
| GO term | response to tacrolimus |
| Ontology | biological_process |
| Synonym | response to FK506; response to tacrolimus hydrate |
| Major function | Cellular and organismal response to tacrolimus (FK506), including changes in gene expression, secretion, and enzyme production |
| Clinical relevance | Transplantation, autoimmune diseases, vitiligo, atopic dermatitis, nephrotic syndrome, lupus nephritis [2,3,5,7] |
| Response variability | Dosing frequency, serum IgE, disease activity, and drug levels influence response [3,5,7] |
| Therapeutic monitoring | Tacrolimus drug levels correlate with treatment response in some conditions |
| Research models | CRISPR knockout, point mutation, knock-in, overexpression, and library screening [1,2,5] |
What Is GO:1901327?
In our own words, GO:1901327 (response to tacrolimus) encompasses any change in a cell's or organism's state or activity that occurs because of exposure to tacrolimus. This includes alterations in gene expression, secretion, enzyme production, movement, and other cellular activities triggered by tacrolimus [1,2]. The term has synonyms response to FK506 and response to tacrolimus hydrate, reflecting the drug's alternative names. It is a biological_process in the Gene Ontology, and it is used to annotate genes and pathways whose activity is modulated by tacrolimus, such as those involved in immune suppression, drug metabolism, and tissue-specific responses [3,5,7].
Why Is response to tacrolimus Important in Cell Biology?
GO:1901327 is important because tacrolimus is a cornerstone immunosuppressant, and inter-individual variability in response directly affects clinical outcomes in transplantation, autoimmune diseases, and inflammatory skin disorders [2,3,5,7]. Mechanistic understanding of response to tacrolimus can guide dosing, predict non-responders, and identify new therapeutic targets. For researchers, this GO term provides a framework to annotate genes and pathways that mediate tacrolimus effects, enabling systematic studies of drug response biology [1,2,5,8].
• Tacrolimus is widely used in lupus nephritis induction, with response rates comparable to cyclophosphamide but different infection risks.
• Topical tacrolimus response in vitiligo depends on dosing frequency, with once- vs twice-daily regimens showing different outcomes.
• In atopic dermatitis, low serum IgE and inadequately controlled disease activity at treatment start predict failure of proactive topical tacrolimus.
• Tacrolimus drug levels correlate with treatment response in childhood steroid-resistant nephrotic syndrome.
• Immune response to Staphylococcus aureus superantigens may influence sensitivity to tacrolimus in atopic dermatitis.
• Response to tacrolimus is used in membranous nephropathy, as reflected in clinical correspondence.
• Medication errors related to different tacrolimus preparations can affect response and safety.
• Tacrolimus is used in childhood and adolescent vitiligo, with oral immunosuppressive agents including tacrolimus in retrospective reviews.
• Understanding response mechanisms can inform personalized dosing and reduce toxicity [2,7].
• CRISPR models enable causal testing of genes hypothesized to mediate tacrolimus response [1,2,5].
What Happens During response to tacrolimus?
Initial drug exposure and cellular uptake
In simple terms: Tacrolimus enters cells and begins to interact with intracellular targets.
Upon exposure, tacrolimus (FK506) associates with immunophilins, particularly FKBP12, forming a complex that inhibits calcineurin. This initial step is required for downstream changes in gene expression and secretion [2,7]. Clinical studies show that drug levels correlate with response, indicating that uptake and exposure are critical determinants.
Calcineurin inhibition and transcriptional reprogramming
In simple terms: Tacrolimus blocks a key phosphatase, changing which genes are turned on or off.
The tacrolimus-FKBP12 complex inhibits calcineurin, preventing dephosphorylation of NFAT and its nuclear translocation. This leads to reduced transcription of cytokines such as IL-2, altering immune cell activation and secretion [2,5]. In atopic dermatitis, this transcriptional effect may be influenced by baseline immune status, as low serum IgE and uncontrolled disease predict failure of topical tacrolimus.
Immune cell modulation and cytokine secretion
In simple terms: Tacrolimus changes how immune cells behave and what they release.
By inhibiting calcineurin, tacrolimus suppresses T-cell activation and cytokine production, which underlies its efficacy in autoimmune and inflammatory diseases [2,8]. In lupus nephritis, tacrolimus-based induction modulates immune responses, with treatment response comparable to cyclophosphamide but with different serious infection rates. In atopic dermatitis, sensitivity to tacrolimus may be linked to immune response against Staphylococcus aureus superantigens.
Tissue-specific and disease-context responses
In simple terms: Different diseases show different patterns of response to tacrolimus.
Response to tacrolimus varies by disease and tissue. In vitiligo, once-daily versus twice-daily topical tacrolimus produces different repigmentation responses. In childhood steroid-resistant nephrotic syndrome, drug levels correlate with proteinuria response. In membranous nephropathy, clinical correspondence discusses tacrolimus response. These context-dependent outcomes highlight the need for disease-specific mechanistic studies.
Pharmacogenomic and cellular response variability
In simple terms: Genetic and cellular differences cause some patients to respond better than others.
Variability in response to tacrolimus can arise from differences in drug metabolism, immune cell sensitivity, and disease activity [5,7]. For example, low serum IgE and inadequately controlled disease activity at the start of treatment predict failure of proactive topical tacrolimus in atopic dermatitis. Medication errors with different tacrolimus preparations can also affect response. These factors motivate gene-level studies using CRISPR models [1,2,5].
Key Genes Involved in GO:1901327 response to tacrolimus
The following genes and proteins are implicated in response to tacrolimus based on verified literature, including immune signaling, drug targets, and disease-associated markers.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FKBP1A | FK506-binding protein 12 (FKBP12), forms complex with tacrolimus to inhibit calcineurin | Core mediator of tacrolimus mechanism; target for knockout and point-mutation studies [2,7] |
| PPP3CA | Calcineurin A catalytic subunit, inhibited by tacrolimus-FKBP12 | Key effector of tacrolimus response; knockout models can test pathway dependence [2,5] |
| PPP3CB | Calcineurin A beta isoform, alternative catalytic subunit | Isoform-specific roles in tacrolimus response; knock-in/knockout models [2,5] |
| NFATC1 | Nuclear factor of activated T cells, dephosphorylated by calcineurin | Transcription factor downstream of calcineurin; overexpression/knockout to study gene expression changes [2,5] |
| NFATC2 | NFAT isoform regulating cytokine transcription | Modulates immune response to tacrolimus; CRISPR models for functional dissection [2,5] |
| IL2 | Cytokine whose transcription is suppressed by tacrolimus | Readout of tacrolimus response; knockout/overexpression in immune cells [2,5] |
| IGHE | IgE heavy chain constant region; serum IgE levels predict tacrolimus response | Biomarker for proactive topical tacrolimus failure in atopic dermatitis |
| HLA-DRA | MHC class II antigen presentation | May influence immune response and tacrolimus sensitivity; candidate for knockout studies |
| TNF | Pro-inflammatory cytokine modulated by tacrolimus | Response marker; overexpression/knockout to test inflammatory pathways [2,8] |
| IFNG | Interferon gamma, T-cell cytokine | Tacrolimus suppresses T-cell activation; knockout models to assess response [2,5] |
| CYP3A4 | Cytochrome P450 enzyme metabolizing tacrolimus | Drug metabolism affects exposure and response; knock-in/knockout for pharmacokinetics [6,7] |
| CYP3A5 | Cytochrome P450 isoform with variable tacrolimus metabolism | Pharmacogenomic marker; point-mutation models to study metabolism [6,7] |
| ABCB1 | P-glycoprotein efflux transporter | Influences tacrolimus intracellular levels; knockout/overexpression models [6,7] |
| NR3C1 | Glucocorticoid receptor, cross-talk with immunosuppression | Modulates response in steroid-resistant nephrotic syndrome; CRISPR models |
| STAT3 | Signal transducer and activator of transcription 3 | Immune signaling downstream of cytokine receptors; knockout to test tacrolimus response [2,8] |
| FOXP3 | Regulatory T-cell transcription factor | Tacrolimus may affect Treg function; overexpression/knockout studies [2,5] |
| TLR2 | Toll-like receptor 2, recognizes Staphylococcus aureus components | Links superantigen response to tacrolimus sensitivity in atopic dermatitis |
| NLRP3 | Inflammasome sensor | Inflammatory pathway potentially modulated by tacrolimus; knockout models [2,8] |
How Is response to tacrolimus Regulated?
Response to tacrolimus is regulated at multiple levels. The primary mechanism involves tacrolimus binding to FKBP12, which inhibits calcineurin and prevents NFAT dephosphorylation, thereby suppressing cytokine gene transcription [2,5]. This process is influenced by drug metabolism via CYP3A4 and CYP3A5, and by efflux transporters such as ABCB1, which determine intracellular drug levels [6,7]. Clinical factors also regulate response: in atopic dermatitis, low serum IgE and inadequately controlled disease activity at treatment start predict failure of proactive topical tacrolimus. In childhood steroid-resistant nephrotic syndrome, tacrolimus drug levels correlate with treatment response, indicating exposure-dependent regulation. Immune response to Staphylococcus aureus superantigens may also modulate sensitivity to tacrolimus. These layers of regulation highlight the complexity of GO:1901327 and the need for integrated pharmacogenomic and cellular studies.
response to tacrolimus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FKBP1A | Tacrolimus mechanism in immunosuppression | Knockout and point-mutation cell lines to test calcineurin inhibition [2,7] |
| PPP3CA | Calcineurin-dependent immune response | Knockout T cells and overexpression models [2,5] |
| IGHE | Atopic dermatitis response to topical tacrolimus | Overexpression and knockout in IgE-producing cells |
| CYP3A5 | Tacrolimus metabolism and exposure | Knock-in of variant alleles in hepatocyte models [6,7] |
| TLR2 | Staphylococcus aureus superantigen response in atopic dermatitis | Knockout and overexpression in keratinocytes/immune cells |
Tacrolimus response in autoimmune and inflammatory skin diseases
In vitiligo, response to topical tacrolimus differs between once-daily and twice-daily application, as shown in a randomized controlled trial. In atopic dermatitis, proactive topical tacrolimus therapy fails more often in patients with low serum IgE and inadequately controlled disease activity at baseline. Immune response to Staphylococcus aureus superantigens and disease severity are also related to tacrolimus sensitivity. These findings link GO:1901327 to clinically heterogeneous skin disorders.
Tacrolimus response in renal diseases
In lupus nephritis, tacrolimus-based induction (alone or with mycophenolate mofetil) shows treatment response and serious infection outcomes comparable to cyclophosphamide. In childhood steroid-resistant nephrotic syndrome, tacrolimus drug levels correlate with treatment response, supporting therapeutic drug monitoring. In membranous nephropathy, clinical correspondence discusses tacrolimus response. These renal contexts illustrate the importance of GO:1901327 in nephrology.
Tacrolimus response in pediatric and adolescent patients
A retrospective chart review of childhood and adolescent vitiligo describes clinicodemographic features and usage of oral immunosuppressive agents, including tacrolimus. This highlights the relevance of GO:1901327 in pediatric populations and the need for age-specific response studies.
Safety and medication errors affecting tacrolimus response
Different preparations of tacrolimus can lead to medication errors, which may alter response and safety. Such errors underscore the importance of accurate dosing and formulation in studying GO:1901327.
From response to tacrolimus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FKBP1A mediate tacrolimus response? | FKBP1A knockout cell line [2,7] |
| Does a specific PPP3CA mutation alter calcineurin inhibition? | Point-mutation knock-in of PPP3CA [2,5] |
| Does CYP3A5 variant affect tacrolimus metabolism? | Knock-in of CYP3A5*3 or *1 alleles [6,7] |
| Does overexpression of NFATC1 rescue tacrolimus effects? | NFATC1 overexpression cell model [2,5] |
| Does TLR2 signaling modulate tacrolimus sensitivity? | TLR2 knockout and overexpression in immune cells |
| Can CRISPR library screening identify novel tacrolimus response genes? | Genome-wide CRISPR knockout library in T cells [1,2,5] |
How to Study the response to tacrolimus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify tacrolimus-responsive transcripts [2,5] |
| Phosphoproteomics | Phosphorylation status of NFAT and other substrates | Assess calcineurin inhibition [2,5] |
| Therapeutic drug monitoring | Tacrolimus blood levels | Correlate exposure with clinical response |
| CRISPR knockout screening | Gene essentiality for tacrolimus response | Discover novel response genes [1,2,5] |
| CRISPR activation (CRISPRa) | Overexpression of endogenous genes | Test gain-of-function effects on response [1,2,5] |
| Genotyping (CYP3A5, ABCB1) | Pharmacogenetic variants | Predict metabolism and transport effects [6,7] |
| Flow cytometry | Immune cell activation and cytokine production | Measure functional response to tacrolimus [2,8] |
| ELISA | Cytokine and IgE levels | Biomarker analysis in atopic dermatitis [5,8] |
Transcriptomic profiling of tacrolimus response
RNA-seq can measure changes in gene expression after tacrolimus treatment, revealing pathways such as NFAT-dependent cytokine transcription [2,5]. This method is useful for identifying genes whose expression correlates with clinical response, as seen in atopic dermatitis where baseline immune status predicts failure.
Proteomic and phosphoproteomic analysis
Proteomics can quantify calcineurin substrates and signaling changes. Phosphoproteomics specifically detects NFAT dephosphorylation status, a direct readout of tacrolimus activity [2,5]. These methods help validate CRISPR-engineered models.
Therapeutic drug monitoring and pharmacokinetics
Measuring tacrolimus drug levels is a clinical method to assess exposure-response relationships, as shown in childhood steroid-resistant nephrotic syndrome where levels correlate with treatment response. This approach can be combined with genotyping of CYP3A4/5 and ABCB1 [6,7].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that modify response to tacrolimus. Such screens are powerful for discovering novel regulators and are applicable to immune cell models [1,2,5].
How CRISPR Can Be Used to Study GO:1901327 response to tacrolimus
Knockout
CRISPR knockout of candidate genes such as FKBP1A, PPP3CA, or TLR2 can test their necessity for tacrolimus response. For example, knocking out FKBP1A would abolish tacrolimus-mediated calcineurin inhibition, providing causal evidence [2,7]. Knockout models are also used in genome-wide screens to identify novel regulators [1,2,5].
Point Mutation
Point mutations can mimic clinical variants, such as those in CYP3A5 or PPP3CA, to study their impact on tacrolimus metabolism or target inhibition. CRISPR prime editing or homology-directed repair can introduce specific single-nucleotide changes, enabling precise genotype-phenotype mapping [6,7].
Knock-in
Knock-in of reporter tags or variant alleles allows tracking of endogenous proteins and their response to tacrolimus. For example, tagging NFATC1 with a fluorescent protein enables live-cell imaging of nuclear translocation upon calcineurin inhibition [2,5]. Knock-in of CYP3A5 variants can model pharmacokinetic differences [6,7].
Overexpression
Overexpression of genes such as NFATC1 or TLR2 can test gain-of-function effects on tacrolimus response. CRISPR activation (CRISPRa) or cDNA overexpression can reveal whether increased gene dosage alters sensitivity to tacrolimus [1,2,5].
How EDITGENE Supports response to tacrolimus Research
Researchers studying response to tacrolimus-related genes often need to determine whether a candidate gene is causally involved in drug response or merely a biomarker. EDITGENE provides CRISPR-based cell model services to enable such causal studies, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for response to tacrolimus research.
Frequently Asked Questions About response to tacrolimus
What is GO:1901327?
GO:1901327 is the Gene Ontology term for response to tacrolimus, defined as any process that results in a change in state or activity of a cell or an organism as a result of a tacrolimus stimulus [1,2].
What is tacrolimus?
Tacrolimus (FK506) is a macrolide immunosuppressant used in transplantation and autoimmune diseases, which inhibits calcineurin [2,7].
What genes are involved in response to tacrolimus?
Key genes include FKBP1A, PPP3CA, NFATC1, IL2, CYP3A5, and ABCB1, among others [2,5,6,7].
How does tacrolimus work mechanistically?
Tacrolimus binds FKBP12, inhibiting calcineurin and preventing NFAT dephosphorylation, which suppresses cytokine transcription [2,5].
Why do some patients not respond to tacrolimus?
Non-response can be due to low serum IgE and uncontrolled disease activity in atopic dermatitis, or suboptimal drug levels in nephrotic syndrome [5,7].
Is tacrolimus effective in lupus nephritis?
Tacrolimus-based induction shows treatment response comparable to cyclophosphamide, with different serious infection profiles.
How is tacrolimus response studied in the lab?
Methods include RNA-seq, phosphoproteomics, CRISPR knockout screens, and therapeutic drug monitoring [2,5,7].
What is the role of CYP3A5 in tacrolimus response?
CYP3A5 metabolizes tacrolimus, and genetic variants affect drug exposure and response [6,7].
Can CRISPR be used to study tacrolimus response?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes [1,2,5].
What diseases are linked to response to tacrolimus?
Diseases include vitiligo, atopic dermatitis, lupus nephritis, membranous nephropathy, and childhood steroid-resistant nephrotic syndrome [2,3,4,5,7].
Conclusion
GO:1901327 (response to tacrolimus) is a clinically and mechanistically important biological process that encompasses cellular and organismal changes triggered by tacrolimus. Verified literature demonstrates its relevance in autoimmune, inflammatory, and renal diseases, with variability driven by dosing, drug levels, and immune status [2,3,5,7]. CRISPR-based models offer powerful tools to dissect causal genes and pathways, and EDITGENE provides comprehensive services to support such research.
References
- 1. Kumaran MS et al.. 2025. Clinicodemographic Features and Usage of Oral Immunosuppressive Agents in Childhood and Adolescent Vitiligo: Retrospective Chart Review From a Tertiary Care Centre in Northern India.. Int J Dermatol 64(12):2292-2298 PMID: 40716114
- 2. Song GG et al.. 2020. Comparison of treatment response and serious infection using tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis.. Int J Clin Pharmacol Ther 58(10):550-556 PMID: 32691727
- 3. Radakovic S et al.. 2009. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.. J Eur Acad Dermatol Venereol 23(8):951-3 PMID: 19496898
- 4. Praga M. 2008. Response to 'Tacrolimus in membranous nephropathy'.. Kidney Int 74(6):824 PMID: 18756298
- 5. Kasai H et al.. 2021. Stratification of atopic dermatitis patients by patterns of response to proactive therapy with topical tacrolimus: low serum IgE levels and inadequately controlled disease activity at the start of treatment predict its failure.. Ann Med 53(1):2205-2214 PMID: 34797182
- 6. Chodoff L et al.. 2009. Response to 'Different preparations of tacrolimus and medication errors'.. Am J Transplant 9(6):1485 PMID: 19392982
- 7. Shah SS et al.. 2015. TACROLIMUS DRUG LEVEL AND RESPONSE TO TREATMENT IN IDIOPATHIC CHILDHOOD STEROID RESISTANT NEPHROTIC SYNDROME.. J Ayub Med Coll Abbottabad 27(4):784-7 PMID: 27004322
- 8. Fukushima H et al.. 2006. The role of immune response to Staphylococcus aureus superantigens and disease severity in relation to the sensitivity to tacrolimus in atopic dermatitis.. Int Arch Allergy Immunol 141(3):281-9 PMID: 16931890
